Glucagon-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a double-blind, randomized, placebo-controlled study

in European Journal of Endocrinology
View More View Less
  • 1 Department of Endocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland
  • | 2 Department of Clinical Research, University Hospital Basel, University of Basel, Basel, Switzerland
  • | 3 Department of Paediatric Endocrinology and Diabetology, University Children’s Hospital Basel, Basel, Switzerland

Correspondence should be addressed to M Christ-Crain; Email: mirjam.christ-crain@usb.ch

*(C Atila and O Gaisl contributed equally to this work)

Restricted access

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

USD  $0.00
USD  $0.00

Background

The differential diagnosis of diabetes insipidus is challenging. The most reliable approaches are copeptin measurements after hypertonic saline infusion or arginine, which is a known growth hormone secretagogue but has recently also been shown to stimulate the neurohypophysis. Similar to arginine, glucagon stimulates growth hormone release, but its effect on the neurohypophysis is poorly studied.

Design

Double-blind, randomized, placebo-controlled trial including 22 healthy participants, 10 patients with central diabetes insipidus, and 10 patients with primary polydipsia at the University Hospital Basel, Switzerland.

Methods

Each participant underwent the glucagon test (s.c. injection of 1 mg glucagon) and placebo test. The primary objective was to determine whether glucagon stimulates copeptin and to explore whether the copeptin response differentiates between diabetes insipidus and primary polydipsia. Copeptin levels were measured at baseline, 30, 60, 90, 120, 150, and 180 min after injection.

Results

In healthy participants, glucagon stimulated copeptin with a median increase of 7.56 (2.38; 28.03) pmol/L, while placebo had no effect (0.10 pmol/L (−0.70; 0.68); P < 0.001). In patients with diabetes insipidus, copeptin showed no relevant increase upon glucagon, with an increase of 0.55 (0.21; 1.65) pmol/L, whereas copeptin was stimulated in patients with primary polydipsia with an increase of 15.70 (5.99; 24.39) pmol/L. Using a copeptin cut-off level of 4.6pmol/L had a sensitivity of 100% (95% CI: 100–100) and a specificity of 90% (95% CI: 70–100) to discriminate between diabetes insipidus and primary polydipsia.

Conclusion

Glucagon stimulates the neurohypophysis, and glucagon-stimulated copeptin has the potential for a safe, novel, and precise test in the differential diagnosis of diabetes insipidus.

Supplementary Materials

 

     European Society of Endocrinology

Sept 2018 onwards Past Year Past 30 Days
Abstract Views 2849 1387 267
Full Text Views 292 146 31
PDF Downloads 390 205 36
  • 1

    Robertson GL Diabetes insipidus: differential diagnosis and management. Best Practice and Research: Clinical Endocrinology and Metabolism 2016 30 205218. (https://doi.org/10.1016/j.beem.2016.02.007)

    • Search Google Scholar
    • Export Citation
  • 2

    Nigro N, Grossmann M, Chiang C, Inder WJ. Polyuria-polydipsia syndrome: a diagnostic challenge. Internal Medicine Journal 2018 48 244253. (https://doi.org/10.1111/imj.13627)

    • Search Google Scholar
    • Export Citation
  • 3

    Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, Pfeiffer AF, Fassnacht M, Störk S, Allolio B. Copeptin in the differential diagnosis of the polydipsia-polyuria syndrome – revisiting the direct and indirect water deprivation tests. Journal of Clinical Endocrinology and Metabolism 2011 96 15061515. (https://doi.org/10.1210/jc.2010-2345)

    • Search Google Scholar
    • Export Citation
  • 4

    Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clinical Chemistry 2006 52 112119. (https://doi.org/10.1373/clinchem.2005.060038)

    • Search Google Scholar
    • Export Citation
  • 5

    Fenske W, Refardt J, Chifu I, Schnyder I, Winzeler B, Drummond J, Ribeiro-Oliveira A, Drescher T, Bilz S & Vogt DR et al.A copeptin-based approach in the diagnosis of diabetes insipidus. New England Journal of Medicine 2018 379 428439. (https://doi.org/10.1056/NEJMoa1803760)

    • Search Google Scholar
    • Export Citation
  • 6

    Fenske WK, Schnyder I, Koch G, Walti C, Pfister M, Kopp P, Fassnacht M, Strauss K, Christ-Crain M. Release and decay kinetics of copeptin vs AVP in response to osmotic alterations in healthy volunteers. Journal of Clinical Endocrinology and Metabolism 2018 103 505513. (https://doi.org/10.1210/jc.2017-01891)

    • Search Google Scholar
    • Export Citation
  • 7

    Winzeler B, Cesana-Nigro N, Refardt J, Vogt DR, Imber C, Morin B, Popovic M, Steinmetz M, Sailer CO & Szinnai G et al.Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet 2019 394 587595. (https://doi.org/10.1016/S0140-6736(1931255-3)

    • Search Google Scholar
    • Export Citation
  • 8

    Refardt J, Christ-Crain M. Copeptin-based diagnosis of diabetes insipidus. Swiss Medical Weekly 2020 150 w20237. (https://doi.org/10.4414/smw.2020.20237)

    • Search Google Scholar
    • Export Citation
  • 9

    Cain JP, Williams GH, Dluhy RG. Glucagon stimulation of human growth hormone. Journal of Clinical Endocrinology and Metabolism 1970 31 222224. (https://doi.org/10.1210/jcem-31-2-222)

    • Search Google Scholar
    • Export Citation
  • 10

    Yuen KC Glucagon stimulation testing in assessing for adult growth hormone deficiency: current status and future perspectives. ISRN Endocrinology 2011 2011 608056. (https://doi.org/10.5402/2011/608056)

    • Search Google Scholar
    • Export Citation
  • 11

    Lewandowski KC, Lewiński A, Skowrońska-Jóźwiak E, Stasiak M, Horzelski W, Brabant G. Copeptin under glucagon stimulation. Endocrine 2016 52 344351. (https://doi.org/10.1007/s12020-015-0783-7)

    • Search Google Scholar
    • Export Citation
  • 12

    Rahim A, Toogood AA, Shalet SM. The assessment of growth hormone status in normal young adult males using a variety of provocative agents. Clinical Endocrinology 1996 45 557562. (https://doi.org/10.1046/j.1365-2265.1996.00855.x)

    • Search Google Scholar
    • Export Citation
  • 13

    Quesada I, Tudurí E, Ripoll C, Nadal A. Physiology of the pancreatic alpha-cell and glucagon secretion: role in glucose homeostasis and diabetes. Journal of Endocrinology 2008 199 519. (https://doi.org/10.1677/JOE-08-0290)

    • Search Google Scholar
    • Export Citation
  • 14

    Leong KS, Walker AB, Martin I, Wile D, Wilding J, MacFarlane IA. An audit of 500 subcutaneous glucagon stimulation tests to assess growth hormone and ACTH secretion in patients with hypothalamic-pituitary disease. Clinical Endocrinology 2001 54 463468. (https://doi.org/10.1046/j.1365-2265.2001.01169.x)

    • Search Google Scholar
    • Export Citation
  • 15

    Hage C, Gan HW, Ibba A, Patti G, Dattani M, Loche S, Maghnie M, Salvatori R. Advances in differential diagnosis and management of growth hormone deficiency in children. Nature Reviews: Endocrinology 2021 17 608624. (https://doi.org/10.1038/s41574-021-00539-5)

    • Search Google Scholar
    • Export Citation
  • 16

    Ach T, Yosra H, Jihen M, Abdelkarim Asma B, Maha K, Molka C, Rouatbi S, Monia Z, Ach K. Cortisol cut-points for the glucagon stimulation test in the evaluation of hypothalamic pituitary adrenal axis. Endocrine Journal 2018 65 935942. (https://doi.org/10.1507/endocrj.EJ18-0147)

    • Search Google Scholar
    • Export Citation
  • 17

    Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Müller B, Christ-Crain M. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. Journal of Clinical Endocrinology and Metabolism 2007 92 26402643. (https://doi.org/10.1210/jc.2006-2046)

    • Search Google Scholar
    • Export Citation
  • 18

    Orme SM, Price A, Weetman AP, Ross RJ. Comparison of the diagnostic utility of the simplified and standard i.m. glucagon stimulation test (IMGST). Clinical Endocrinology 1998 49 773778. (https://doi.org/10.1046/j.1365-2265.1998.00610.x)

    • Search Google Scholar
    • Export Citation
  • 19

    Sawin CT, Silbert CK, Mitchell ML. The effect of glucose on the growth hormone response to glucagon and propranolol-glucagon in normal subjects. Metabolism: Clinical and Experimental 1975 24 10091014. (https://doi.org/10.1016/0026-0495(7590093-1)

    • Search Google Scholar
    • Export Citation
  • 20

    Glick SM Hypoglycemic threshold for human growth hormone release. Journal of Clinical Endocrinology and Metabolism 1970 30 619623. (https://doi.org/10.1210/jcem-30-5-619)

    • Search Google Scholar
    • Export Citation
  • 21

    Hage M, Kamenický P, Chanson P. Growth hormone response to oral glucose load: from normal to pathological conditions. Neuroendocrinology 2019 108 244255. (https://doi.org/10.1159/000497214)

    • Search Google Scholar
    • Export Citation
  • 22

    Wang XM, Tresham JJ, Congiu M, Coghlan JP, Scoggins BA. Somatostatin centrally inhibits vasopressin secretion during haemorrhage. Brain Research 1987 436 199203. (https://doi.org/10.1016/0006-8993(8791577-0)

    • Search Google Scholar
    • Export Citation
  • 23

    Feldman M, Samson WK, O’Dorisio TM. Apomorphine-induced nausea in humans: release of vasopressin and pancreatic polypeptide. Gastroenterology 1988 95 721726. (https://doi.org/10.1016/s0016-5085(8880020-9)

    • Search Google Scholar
    • Export Citation
  • 24

    Koch KL, Summy-Long J, Bingaman S, Sperry N, Stern RM. Vasopressin and oxytocin responses to illusory self-motion and nausea in man. Journal of Clinical Endocrinology and Metabolism 1990 71 12691275. (https://doi.org/10.1210/jcem-71-5-1269)

    • Search Google Scholar
    • Export Citation